
    
      This is a phase 2, double-blinded, randomized, placebo-controlled, multi-center trial of
      Gamunex-C IVIG as mono-therapy for HMGCR necrotizing myopathy. Up to 10 treatment-na√Øve
      patients will be enrolled and randomized to receive either Gamunex-C IVIG dosed at 2g/kg or
      placebo at week 0 and week 4. The primary efficacy outcome is the percentage of patients at
      week 8 with at least minimal improvement per the 2016 ACR/EULAR myositis clinical response
      criteria.
    
  